Stock BIOA B BIOARCTIC AB
Add to a list
To use this feature you must be a member
Log inSign up

All News BioArctic AB

Equities

BIOA B

SE0010323311

Delayed Nasdaq Stockholm
Other stock markets
 04:29:39 30/04/2024 pm IST 		5-day change 1st Jan Change
195 SEK -2.01% Intraday chart for BioArctic AB +3.50% -27.18%
22/04 Nordic Stocks Closed Up Monday; Getinge Series B Climbed Highest DJ
20/04 BioArctic AB and Eisai Co., Ltd. Sign Research Evaluation Agreement Regarding BAN2802 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioArctic AB - Leqembi revenue totaled JPY 2.83 billion in the first quarter 2024
AQ
Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024
AQ
Nordic Stocks Closed Up Monday; Getinge Series B Climbed Highest
DJ
BioArctic and Eisai sign research evaluation agreement regarding BAN2802
AQ
BioArctic AB and Eisai Co., Ltd. Sign Research Evaluation Agreement Regarding BAN2802
CI
Notice of Annual General Meeting in BioArctic AB (publ)
AQ
BioArctic publishes the Annual Report for 2023
AQ
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
AQ
Nordic Shares Moved Upward Monday; Invisio Led Increases
DJ
Nordic Stocks Rose Friday; BioArctic Series B Climbed Highest
DJ
BioArctic's focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm
AQ
BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug
MT
Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed
AQ
BioArctic AB - Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons
AQ
Nordic Stocks Declined Friday; BioArctic Series B Took Biggest Hit
DJ
BioArctic Flags Delay in EU Health Regulator's Evaluation of Azlheimer’s Disease Drug
MT
Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons
AQ
Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer's European Grand Prix for his contributions to science and treatment of Alzheimer's disease
AQ
New data on lecanemab presented at the 2024 AD/PD™ congress
AQ
BioArctic AB and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIOA B Stock
  4. News BioArctic AB